Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Free Cash Flow (2019 - 2025)

Historic Free Cash Flow for Fulcrum Therapeutics (FULC) over the last 7 years, with Q3 2025 value amounting to -$14.3 million.

  • Fulcrum Therapeutics' Free Cash Flow rose 2569.7% to -$14.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.3 million, marking a year-over-year decrease of 57949.73%. This contributed to the annual value of -$2.5 million for FY2024, which is 9727.13% up from last year.
  • Per Fulcrum Therapeutics' latest filing, its Free Cash Flow stood at -$14.3 million for Q3 2025, which was up 2569.7% from -$13.9 million recorded in Q2 2025.
  • Fulcrum Therapeutics' 5-year Free Cash Flow high stood at $58.9 million for Q2 2024, and its period low was -$28.2 million during Q3 2022.
  • Moreover, its 5-year median value for Free Cash Flow was -$21.0 million (2023), whereas its average is -$16.7 million.
  • Per our database at Business Quant, Fulcrum Therapeutics' Free Cash Flow crashed by 39902.11% in 2021 and then surged by 38073.88% in 2024.
  • Over the past 5 years, Fulcrum Therapeutics' Free Cash Flow (Quarter) stood at -$22.4 million in 2021, then increased by 11.46% to -$19.8 million in 2022, then decreased by 17.28% to -$23.2 million in 2023, then increased by 27.44% to -$16.9 million in 2024, then grew by 15.27% to -$14.3 million in 2025.
  • Its Free Cash Flow stands at -$14.3 million for Q3 2025, versus -$13.9 million for Q2 2025 and -$15.3 million for Q1 2025.